These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 30301694)

  • 1. Identifying the Optimal Candidate for Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer: Results from a Large, Multi-institutional Analysis.
    Fossati N; Suardi N; Gandaglia G; Bravi CA; Soligo M; Karnes RJ; Shariat S; Battaglia A; Everaerts W; Joniau S; Van Poppel H; Rajarubendra N; Gill IS; Larcher A; Mottrie A; Schmautz M; Heidenreich A; Kalz A; Osmonov D; Juenemann KP; Herlemann A; Gratzke C; Stief C; Montorsi F; Briganti A
    Eur Urol; 2019 Jan; 75(1):176-183. PubMed ID: 30301694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term Outcomes of Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Not as Good as Previously Thought.
    Bravi CA; Fossati N; Gandaglia G; Suardi N; Mazzone E; Robesti D; Osmonov D; Juenemann KP; Boeri L; Jeffrey Karnes R; Kretschmer A; Buchner A; Stief C; Hiester A; Nini A; Albers P; Devos G; Joniau S; Van Poppel H; Shariat SF; Heidenreich A; Pfister D; Tilki D; Graefen M; Gill IS; Mottrie A; Karakiewicz PI; Montorsi F; Briganti A
    Eur Urol; 2020 Nov; 78(5):661-669. PubMed ID: 32624288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Definition and Impact on Oncologic Outcomes of Persistently Elevated Prostate-specific Antigen After Salvage Lymph Node Dissection for Node-only Recurrent Prostate Cancer After Radical Prostatectomy: Clinical Implications for Multimodal Therapy.
    Bravi CA; Droghetti M; Fossati N; Gandaglia G; Suardi N; Mazzone E; Cucchiara V; Scuderi S; Barletta F; Schiavina R; Osmonov D; Juenemann KP; Boeri L; Karnes RJ; Kretschmer A; Buchner A; Stief C; Hiester A; Nini A; Albers P; Devos G; Joniau S; Van Poppel H; Grubmüller B; Shariat SF; Heidenreich A; Pfister D; Tilki D; Graefen M; Gill IS; Mottrie A; Karakiewicz PI; Montorsi F; Briganti A
    Eur Urol Oncol; 2022 Jun; 5(3):285-295. PubMed ID: 34176768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years.
    Suardi N; Gandaglia G; Gallina A; Di Trapani E; Scattoni V; Vizziello D; Cucchiara V; Bertini R; Colombo R; Picchio M; Giovacchini G; Montorsi F; Briganti A
    Eur Urol; 2015 Feb; 67(2):299-309. PubMed ID: 24571959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing the Best Surgical Template at Salvage Pelvic Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: When Can Bilateral Dissection be Omitted? Results from a Multi-institutional Series.
    Bravi CA; Fossati N; Gandaglia G; Suardi N; Mazzone E; Robesti D; Osmonov D; Juenemann KP; Boeri L; Jeffrey Karnes R; Kretschmer A; Buchner A; Stief C; Hiester A; Nini A; Albers P; Devos G; Joniau S; Van Poppel H; Shariat SF; Heidenreich A; Pfister D; Tilki D; Graefen M; Gill IS; Mottrie A; Karakiewicz PI; Montorsi F; Briganti A
    Eur Urol; 2020 Dec; 78(6):779-782. PubMed ID: 32624281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11C]choline positron emission tomography/computed tomography.
    Rigatti P; Suardi N; Briganti A; Da Pozzo LF; Tutolo M; Villa L; Gallina A; Capitanio U; Abdollah F; Scattoni V; Colombo R; Freschi M; Picchio M; Messa C; Guazzoni G; Montorsi F
    Eur Urol; 2011 Nov; 60(5):935-43. PubMed ID: 21840116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Robotic salvage lymph node dissection for nodal-only recurrences after radical prostatectomy: Perioperative and early oncological outcomes.
    Linxweiler J; Saar M; Al-Kailani Z; Janssen M; Ezziddin S; Stöckle M; Siemer S; Ohlmann CH
    Surg Oncol; 2018 Jun; 27(2):138-145. PubMed ID: 29937163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mid-term Outcomes Following Salvage Lymph Node Dissection for Prostate Cancer Nodal Recurrence Status Post-radical Prostatectomy.
    Zattoni F; Nehra A; Murphy CR; Rangel L; Mynderse L; Lowe V; Kwon E; Karnes RJ
    Eur Urol Focus; 2016 Dec; 2(5):522-531. PubMed ID: 28723518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficiency of repeat salvage lymph node dissection for recurrence of prostate cancer using PSMA-radioguided surgery (RGS) after prior salvage lymph node dissection with or without initial RGS support.
    Falkenbach F; Knipper S; Koehler D; Ambrosini F; Steuber T; Graefen M; Budäus L; Eiber M; Lunger L; Lischewski F; Heck MM; Maurer T
    World J Urol; 2023 Sep; 41(9):2343-2350. PubMed ID: 37515651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Which Patients with Prostate Cancer and Lymph Node Uptake at Preoperative Prostate-specific Membrane Antigen Positron Emission Tomography/Computerized Tomography Scan Are at a Higher Risk of Prostate-specific Antigen Persistence After Radical Prostatectomy? Identifying Indicators of Systemic Disease by Integrating Clinical, Magnetic Resonance Imaging, and Functional Imaging Parameters.
    Mazzone E; Gandaglia G; Robesti D; Rajwa P; Gomez Rivas J; Ibáñez L; Soeterik TFW; Bianchi L; Afferi L; Kesch C; Darr C; Guo H; Zhuang J; Zattoni F; Fendler WP; Amparore D; Huebner NA; Giesen A; Joniau S; Schiavina R; Brunocilla E; Mattei A; Dal Moro F; Moreno Sierra J; Porpiglia F; Picchio M; Chiti A; van den Bergh R; Shariat SF; Montorsi F; Briganti A
    Eur Urol Oncol; 2024 Apr; 7(2):231-240. PubMed ID: 37689506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is 11C-choline Positron Emission Tomography/Computed Tomography Accurate to Detect Nodal Relapses of Prostate Cancer After Biochemical Recurrence? A Multicentric Study Based on Pathologic Confirmation from Salvage Lymphadenectomy.
    Oderda M; Joniau S; Palazzetti A; Falcone M; Melloni G; Van Den Bossche H; Deconinck S; Zattoni F; Karnes RJ; Gontero P
    Eur Urol Focus; 2018 Mar; 4(2):288-293. PubMed ID: 30205893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncological outcome of patients treated with spot-specific salvage lymphnode dissection (sLND) for positron-emission tomography (PET)-positive prostate cancer (PCa) relapse.
    Hiester A; Nini A; Niegisch G; Arsov C; Hautzel H; Antke C; Schimmöller L; Albers P; Rabenalt R
    World J Urol; 2019 Oct; 37(10):2081-2090. PubMed ID: 30643974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of salvage extended lymph node dissection in patients with rising PSA and PET/CT scan detected nodal recurrence of prostate cancer.
    Porres D; Pfister D; Thissen A; Kuru TH; Zugor V; Buettner R; Knuechel R; Verburg FA; Heidenreich A
    Prostate Cancer Prostatic Dis; 2017 Mar; 20(1):85-92. PubMed ID: 27824042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patterns of Clinical Recurrence of Node-positive Prostate Cancer and Impact on Long-term Survival.
    Nini A; Gandaglia G; Fossati N; Suardi N; Cucchiara V; Dell'Oglio P; Cazzaniga W; Luzzago S; Montorsi F; Briganti A
    Eur Urol; 2015 Nov; 68(5):777-84. PubMed ID: 25959166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contemporary role of salvage lymphadenectomy in patients with recurrence following radical prostatectomy.
    Abdollah F; Briganti A; Montorsi F; Stenzl A; Stief C; Tombal B; Van Poppel H; Touijer K
    Eur Urol; 2015 May; 67(5):839-49. PubMed ID: 24698524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Standard of Care Versus Metastases-directed Therapy for PET-detected Nodal Oligorecurrent Prostate Cancer Following Multimodality Treatment: A Multi-institutional Case-control Study.
    Steuber T; Jilg C; Tennstedt P; De Bruycker A; Tilki D; Decaestecker K; Zilli T; Jereczek-Fossa BA; Wetterauer U; Grosu AL; Schultze-Seemann W; Heinzer H; Graefen M; Morlacco A; Karnes RJ; Ost P
    Eur Urol Focus; 2019 Nov; 5(6):1007-1013. PubMed ID: 29530632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Defining the optimal template of salvage lymph node dissection for unilateral pelvic nodal recurrence of prostate cancer following radical prostatectomy.
    Van Eecke H; Devos G; Vansevenant B; Vander Stichele A; Devlies W; Berghen C; Everaerts W; De Meerleer G; Joniau S
    Int J Urol; 2023 Jan; 30(1):92-99. PubMed ID: 36305586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Underestimation of Positron Emission Tomography/Computerized Tomography in Assessing Tumor Burden in Prostate Cancer Nodal Recurrence: Head-to-Head Comparison of
    Fossati N; Scarcella S; Gandaglia G; Suardi N; Robesti D; Boeri L; Karnes RJ; Heidenreich A; Pfister D; Kretschmer A; Buchner A; Stief C; Battaglia A; Joniau S; Van Poppel H; Osmonov D; Juenemann KP; Shariat S; Hiester A; Nini A; Albers P; Tilki D; Graefen M; Gill IS; Mottrie A; Galosi AB; Montorsi F; Briganti A
    J Urol; 2020 Aug; 204(2):296-302. PubMed ID: 32068488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PSMA-positive nodal recurrence in prostate cancer : Salvage radiotherapy is superior to salvage lymph node dissection in retrospective analysis.
    Schmidt-Hegemann NS; Buchner A; Eze C; Rogowski P; Schaefer C; Ilhan H; Li M; Fendler WP; Bartenstein P; Ganswindt U; Stief C; Belka C; Kretschmer A
    Strahlenther Onkol; 2020 Jul; 196(7):637-646. PubMed ID: 32211942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.